Engineered immune cells take aim at stubborn solid tumors
NCT ID NCT07672483
First seen Jun 29, 2026 · Last updated Aug 14, 2026 · Updated 33 times
Summary
This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL-12. After a short course of chemotherapy to prepare the body, the modified cells are infused back into the patient. The goal is to see if these cells can safely attack tumors and at what dose they work best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IL-12 GEMys (genetically engineered myeloid cells)
- What this could lead to
- If it works, this could point toward a new treatment for hard-to-treat solid tumors by using the body's own immune cells to fight cancer.
- What could go wrong
- This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet proven. The treatment involves chemotherapy and cell infusion, which carry risks like infection and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMOR MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States